In addition to the positive outcome for dyslipidemia, recently, PPAR α activation by pemafibrate treatment was also suggested as one of the promising therapeutic targets in the prevention of ocular ischemic diseases (Lee et al., 2021b). This evidence concerns the gene PPARA and metabolic syndrome.